Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
The primary outcome measure will be time to first relapse on study in subjects treated with Rebif 44 mcg three times per week compared with subjects not treated over 96 weeks.
Relapses
Who could take part
Relapsing and progressive
Inclusion: - Definite RRMS or SPMS with relapses Exclusion: - Subject received any cytokine or anti-cytokine therapy within the 3 months prior to Study Day 1 (SD1, week 0)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of the study is to asses if treatment with Rebif 44 mcg three times per week compared with subjects not treated during 96 weeks can maintain or prolong clinical or MRI stability after previous treatment with mitoxantrone.
Loading reviews and guidelines…
Related trials
- DESIRE MS
Phase 3 · Recruiting
Still running
- Study to Evaluate Oral BIIB061 Added to Interferon-beta1 …
Phase 2 · Withdrawn
Stopped: not working
- Evaluating the Use of Prednisone to Decrease Pegylated In…
Phase 4 · Status unknown
Result in a paper, not read yet
- PROmyBETAapp
Completed
Result in a paper, not read yet
- TOLERVIT-MS
Phase 1 · Status unknown
Result in a paper, not read yet
- SYNERGY
Phase 2 · Completed
Met its main goal
History
Started
May 2005
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error